StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research note published on Monday. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a 52 week low of $0.00 and a 52 week high of $0.00. The stock has a market cap of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61.
About Genocea Biosciences
Featured Stories
- Five stocks we like better than Genocea Biosciences
- How to Calculate Stock Profit
- First Solar Stock: The Dawn of a New Rally in Share Prices
- What Are Trending Stocks? Trending Stocks Explained
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.